| Autor: |
YAMAMOTO, Yasuyoshi, IIZUKA, Hidehiko, YAMAMOTO, Masayuki, TASAKA, Kachio, SUGAHARA, Katsuhiko |
| Jazyk: |
angličtina |
| Rok vydání: |
1990 |
| Předmět: |
|
| Zdroj: |
山梨医科大学雑誌 = 山梨医科大学雑誌. 5(1):25-34 |
| ISSN: |
0912-0025 |
| Popis: |
We performed immunochemotherapy using a continuous infusion of recombinant interleukin 2 (IL2) and intermittent one-shot-injections of Adriamycin (ADR) administered directly to the hepatic artery in 6 cases of advanced hepatocellular carcinoma (HCC). Although the observation periods were short, the tumors reduced in size; most notably, a massive tumor in the right lobe disappeared in one case. After reviewing the 6 patients with HCC, we demonstrated a possible cause of ADR as a kind of immuno-modifier. In an in vitro study, the susceptibility of subpopulations of lymphocytes to ADR was variable with the suppressor T cell being more susceptible to ADR compared to the helper T cell. In HCC patients, the ratio of the suppressor T cells to the helper T cells (suppressor/helper ratio) was significantly higher than that of the healthy controls. Thus, following the administration of the optimal dose of ADR, specific decrease in the suppressor T cell and increase in the helper T cell in response to ADR can be obtained for the recovery of the suppressor/helper ratio. Moreover, ADR-treated lymphocytes of HCC patients exhibited constant killer activity in the presence of IL2. Although the optimal dose of ADR for clinical use may be within a very narrow range, ADR combined with IL2 following tumor mass-reduction treatments may restore the immunity of advanced HCC patients and prolong their survival. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
